Purpose of review Extracellular vesicles carry bioactive molecules that can be transferred between cells and tissues. The purpose of this review is to describe how extracellular vesicles regulate functions of cells in cartilage and other joint tissues. The potential application of extracellular vesicles in the treatment of osteoarthritis and as biomarkers will also be discussed.
INTRODUCTION
Osteoarthritis represents the most common musculoskeletal disorder [1] . It is a complex and multifaceted disease, characterized by the degradation of articular cartilage, subchondral bone remodeling, joint inflammation and changes in meniscus and ligaments [2] . Various risk factors for osteoarthritis have been identified and these include aging, joint injury, excessive chronic mechanical stress, genetic factors and metabolic disorders [3] . Although several pathogenesis pathways have been characterized [4] , current knowledge is incomplete and has not led to effective approaches for prevention or treatment. These limitations can be overcome by advances in the understanding of molecular mechanisms that are involved in the maintenance of joint tissues which involves communication of cells within the different joint tissues. Cells are able to communicate with neighboring or distant cells through cytokines and hormones. Recently, extracellular vesicles that are released from cells have attracted attention as novel a mechanism of cell-cell communication.
Extracellular vesicles transfer bioactive molecules to recipient cells to modulate their activity [5] . In this review, we focus on the role of extracellular vesicles in cell-cell communication within and among joint tissues during homeostasis and osteoarthritis pathogenesis and address the potential therapeutic application of extracellular vesicles. consequence of cell damage or the result of dynamic plasma membrane turnover. However, recently, cell-cell communication via extracellular vesicles has become the center of attention in research of diseases and tissue repair. Extracellular vesicles contain bioactive molecules, including proteins, mRNAs, microRNAs, lipids and DNA [6] . Extracellular vesicles have been classified depending on size and biogenesis pathway. Exosomes are small extracellular vesicles (30-150 nm in diameter) that are generated in multivesicular endosome/multivesicular bodies and are released when these compartments fuse with the plasma membrane. Microvesicles/microparticles (50-1000 nm in diameter) are released by budding from the surface of the plasma membrane [7] . Exosome biogenesis is a very tightly regulated process governed by multiple signaling molecules, and begins with receptor activation that is unique to each cell type [8] . Detailed and conclusive characterization of the various types of extracellular vesicles has not yet been accomplished. The International Society for Extracellular Vesicles provided a minimal set of biochemical, biophysical and functional standards [9] . Size alone cannot distinguish exosomes from microvesicles [10] . Furthermore, some proteins previously used as exosome markers, such as major histocompatibility complex class II or class I molecules, heatshock proteins, flotillins or actin, are present in all types of extracellular vesicles, and thus cannot be considered as either exosome or even extracellular vesicle-specific markers [11] . New specific markers of medium and large size extracellular vesicles (e.g. actinins), of endosome-derived exosomes (coexpressing three tetraspanins CD9/CD63/CD81 and including TSG101 and syntenin-1), and of nonendosomal extracellular vesicles (some integrins) have been proposed [7, 11] . There remains a continuing need to better understand the molecular mechanisms of the biogenesis and release of extracellular vesicles and to discover better markers for the various types. The released extracellular vesicles have surface receptors/ligands of their cell source and have potential to interact with specific target cells [6] . Extracellular vesicles directly stimulate target cells by receptormediated interactions or transfer of the enclosed bioactive molecules into the recipient cell [8] .
EXTRACELLULAR VESICLES FROM CARTILAGE AND CHONDROCYTES
Extracellular vesicles have long been known to be present in the pericellular matrix of articular cartilage and growth plate cartilage [12] [13] [14] [15] [16] [17] . Various terms have been used to describe them, including matrix vesicles (MaVs), articular cartilage-derived extracellular vesicles (ACEVs) or apoptotic bodies but there is no conclusive distinction (Table 1 ) [9] . Originally, MaVs were described in growth plate as derived from budding or disintegrating cells that are associated with hydroxyapatite deposition. Alkaline phosphatase activity is abundant in MaVs and is used as a marker for their identification [13] . MaVs also contain pyrophosphate-generating nucleoside triphosphate (NTP) pyrophosphohydrolase activities. MaVs can be isolated from collagenase-digested articular cartilage and separated from chondrocytes by differential centrifugation and used for KEY POINTS Extracellular vesicles are released from chondrocytes through various mechanisms, including autophagy and apoptosis.
Extracellular vesicles from chondrocytes can play a role in abnormal articular cartilage mineralization.
Extracellular vesicles from MSCs can be enriched for certain bioactive molecules, such as miRNAs and used for tissue repair and in the treatment of osteoarthritis. functional, biochemical and ultrastructural studies [18] . Isolated MaV can incorporate calcium, hydrolyze adenosine triphosphate or other nucleotide triphosphates, and facilitate precipitation of hydroxylapatite [19] . Although MaVs from different sources are heterogeneous [20] , they are similar with respect to the capacity to mineralize matrix [12, 17] . ACEVs have been shown to have a physiological function in endochondral bone development and pathologic role in calcium crystal deposition in articular cartilage [21 && ]. The majority of the proteome was shared by extracellular vesicles isolated from normal and osteoarthritis cartilage, but immunoglobulins and complement components were present only in osteoarthritis ACEV which also contained lower levels of matrix proteoglycans [22] . Importantly, the ACEV proteome shares fewer similarities with exosomal proteomes. The heterotrimeric G proteins, HSP70 and 90 and members of the tetraspanin family such as CD9, CD63 and CD81 that are particularly characteristic of exosomes were not seen in ACEV [22] . CD9, CD63 and CD81 were previously considered to be specific markers for exosomes; however, in recent proteomics comparison, these proteins were observed in all extracellular vesicles including microvesicle and apoptotic bodies [11, 23] .
RNAs are also packaged in extracellular vesicles and are transferable genetic material from tissue to tissue and from human to human [5] . RNAs are protected from degradation by the lipid membrane of the extracellular vesicles. Coding and noncoding small RNAs in extracellular vesicles were in proportions that differed from parent cells with an enrichment of specific miRNAs suggesting that miRNAs are selectively packaged into extracellular vesicles. For example, small RNAs such as miRNAs were enriched in extracellular vesicles isolated from cultures of costochondral growth zone chondrocytes, whereas large RNAs such as 18S and 28S rRNA were not detected [24 & ]. Extracellular vesicles from normal articular cartilage contain full-length mRNAs for factor XIIIA, type II transglutaminase, collagen II, aggrecan, ANKH inorganic pyrophosphate transport regulator and glyceraldehyde-3-phosphate dehydrogenase. When transferred to chondrocytes, ACEVderived RNA was internalized. This was associated with changes in the expression of alkaline phosphatase and osteopontin [25] .
The mechanisms of ACEV formation include apoptosis which is increased in osteoarthritisaffected cartilage [26] . Chondrocyte-derived apoptotic bodies contain alkaline phosphatase and NTP pyrophosphohydrolase activities, and can precipitate calcium [27] . A role of apoptosis in generating this type of ACEV has been demonstrated in experiments where apoptosis was induced by the nitric oxide donor sodium nitroprusside or antibody to the Fas antigen [27] . Extracellular vesicles accumulate around apoptotic cells (Fig. 1) . The levels of pyrophosphate produced by apoptotic bodies were increased by pretreatment of the chondrocytes with transforming growth factor-b and decreased by IL-1 interleukin-1beta (IL-1b) [27] . It has also been suggested that ACEV from primary articular chondrocytes can be generated through the autophagy pathway [28] . In normal but not in osteoarthritis chondrocytes, rapamaycin, which induces autophagy by inhibiting mTOR signaling, increased the release of ACEV that contained LC3, a marker of autophagosomes [28] . Release of ACEV was inhibited by gene knock down of caspase-3, suggesting an involvement of apoptosis-related mechanisms [28] . Thus, ACEVs include various types of extracellular vesicles that differ in mechanism of generation and apparently in molecular content.
More detailed information about calcium crystal deposition by ACEV is presented in a recent review [21 && ]. A database of MaV proteins also provides The concept that extracellular vesicles can mediate communication among cells from different joint tissues has thus far only been tested in a limited number of examples. Exosomes from IL-1b-stimulated synoviocytes significantly upregulated matrix metalloproteinase (MMP)-13 and ADAMTS-5 expression in articular chondrocytes, and downregulated COL2A1 and ACAN compared with synoviocyte-derived exosomes that were not simulated with IL-1 [30] (Fig. 2) . Migration and tube formation activity were significantly higher in human umbilical vein endothelial cells treated with the exosomes from IL-1b-stimulated synoviocytes, which also induced significantly more proteoglycan release from cartilage explants. Inflammatory cytokines, IL-6, MMP-3 and vascular endothelial growth factor in exosomes were only detectable at low level. IL-1b, tumor necrosis factor-a MMP-9 and MMP-13 were not detectable in exosomes. NanoString analysis showed that levels of 50 miRNAs were differentially expressed in exosomes from IL-1b-stimulated synoviocytes compared to nonstimulated cells [30] .
EXTRACELLULAR VESICLES IN SYNOVIAL FLUID AS POTENTIAL OSTEOARTHRITIS BIOMARKERS
Extracellular vesicles are abundant in synovial fluid, and can be derived from resident cells in joint tissues and from leukocytes that infiltrate arthritis-affected joints. Synovial fluid extracellular vesicles modulate the release of chemokines and cytokines in synoviocytes [31,32 && ]. The expression patterns of miRNAs in synovial fluid of osteoarthritis were similar to miRNAs secreted by synovial tissues [33] . A recent microarray analysis of miRNAs in synovial fluid exosomes showed that in samples from female osteoarthritis patients, miR-16-2-3p was upregulated and miR-26a-5p, miR-146a-5p and miR-6821-5p were downregulated. In synovial fluid from male osteoarthritis patients, miR-6878-3p was downregulated and miR-210-5p was upregulated. Thus, synovial fluid exosomal miRNA content is altered in patients with osteoarthritis and these changes are sex specific [34 && ]. This is the first study to analyze exosomal molecules as biomarkers in osteoarthritis. Future studies need to address the possibility of detecting joint-derived extracellular vesicles in blood and of identifying the cellular origin of extracellular vesicles. This has potential to detect tissue-specific changes as biomarkers for osteoarthritis.
EXTRACELLULAR VESICLES IN THERAPEUTIC APPLICATIONS
Mesenchymal stem cells (MSCs) have been used successfully in tissue engineering approaches to treat cartilage lesions and osteoarthritis in animal [35] and human studies [36, 37] . These beneficial functions of MSC are at least in part mediated by paracrine effects of cytokines and growth factors that decreased inflammation, enhanced progenitor cell proliferation and improved tissue repair. In a mouse model of myocardial ischemia/reperfusion injury, it was first demonstrated that the protective paracrine effect was mediated by secreting exosomes [38] .
Since then, additional studies have demonstrated that extracellular vesicles from MSCs have therapeutic effects [39] [40] [41] . We reported that MSC-derived extracellular vesicles promote skeletal muscle repair and bone fracture healing in mouse models through acceleration of biological functions such as angiogenesis and cell differentiation [32 && ,42] . Exosomes can be used in therapeutic approaches, either from specific cell types such as MSC or from cells that are transfected with genes that have therapeutic potential to enrich for RNA levels for the gene of interest. Exosomes derived from synovial membrane MSC promoted chondrocyte proliferation and migration but inhibited their secretion of extracellular matrix (ECM). Wnt5a and Wnt5b carried by exosomes activated the alternative Wnt signaling pathway and enhanced proliferation and migration of chondrocytes but significantly decreased ECM secretion. We previously reported that miRNAs, in particular miRNA-140, one of the most abundant miRNAs in chondrocytes are important regulators of cartilage homeostasis [43, 44] . Exosomes that were prepared from cells that were transduced with lentiviral miR-140-5p, enhanced the proliferation and migration of articular chondrocytes and reduced osteoarthritis severity in a rat model [45 && ]. Human embryonic MSC exosomes promoted cartilage regeneration in a rat osteochondral defect model [46] . In that study, MSC exosomes accelerated neotissue filling and enhanced synthesis of type II collagen and sulphated glycosaminoglycans. By the end of 12 weeks, exosome-treated rats displayed complete restoration of cartilage and subchondral bone.
Exosomes from conditioned culture media of embryonic stem cell-derived MSC (ESC-MSC) maintained the chondrocyte phenotype by increasing collagen type II synthesis and decreasing ADAMTS5 expression in the presence of IL-1b. Intra-articular injection of ESC-MSC alleviated cartilage destruction and matrix degradation in the destabilizing the medial meniscus (DMM) model. Immunocytochemistry revealed colocalization of the exosomes and collagen type II-positive chondrocytes. Subsequent intra-articular injection of exosomes derived from ESC-MSC successfully protected against cartilage destruction in the DMM model. The exosomes from ESC-MSC exert a beneficial therapeutic effect on osteoarthritis by balancing the synthesis and degradation of chondrocyte ECM, which in turn provides a new target for osteoarthritis drug and drug-delivery system development [47] . This study demonstrated the utility of MSC exosomes as a ready-to-use and 'cell-free' therapeutic alternative to cell-based MSC therapy.
FUTURE PERSPECTIVES
The role of extracellular vesicles in joint homeostasis and osteoarthritis pathogenesis is of great interest and further research on this topic has potential implications for the discovery of novel biomarkers and therapeutic approaches. Currently, this field is at an early stage and the topic that seems most advanced is the use of extracellular vesicles as therapeutics. Key questions that need to be investigated are: regulation of the types, amounts and compositions of extracellular vesicles that are generated and released by cells; stability of extracellular vesicles in the various joint tissue environments and transport of extracellular vesicles through dense ECM structures such as in cartilage; mechanisms of recognition and internalization by cells; the role of extracellular vesicles in joint homeostasis and pathogenesis; markers of extracellular vesicles in synovial fluid or blood that allow tracking their cellular origin and thus profiling the status of these cells.
CONCLUSION
Extracellular vesicles are present in articular cartilage and synovial fluid and represent a heterogeneous mixture that varies in regard to mechanism of generation and molecular content. Synovial fluid extracellular vesicles are potential new osteoarthritis biomarkers. Composition of extracellular vesicles from osteoarthritis cartilage appears to be altered and may contribute to abnormal mineral and crystal deposition. Extracellular vesicles are released from synovial fibroblasts and affect gene expression in chondrocytes. The pattern of mRNAs and miRNAs in extracellular vesicles can be altered by stimulation or gene transduction of cells and thus be designed to specifically change the function of target cells for therapeutic use.
